New first-line therapy for dMMR/MSI-H CRC
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-020-00464-y
Abstract: Nature reviews | CliniCal OnCOlOgy The antiPD-1 antibody pembrolizumab was approved by the FDA for patients with previously treated advancedstage mismatch repair deficient (dMMR) or microsatellite instabilityhigh (MSIH) solid tumours in May 2017. This landmark… read more here.
Keywords: chemotherapy; dmmr msih; patients dmmr; pembrolizumab ... See more keywords